|By PR Newswire||
|September 1, 2014 10:58 AM EDT||
DUBLIN, Sept. 1, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the " Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014" report to their offering.
This report is a comprehensive analysis and market study of new developments relating to early-stage minimally-invasive biomarkers in Alzheimer's disease, which have been 'functionally reviewed' alongside existing AD drugs and candidates in the AD drug pipeline, and applicable commercial AD diagnostics.
New advances have been made in the discovery and validation of biomarkers in Alzheimer's disease (AD), offering much-needed opportunities to accelerate disease research, drug discovery and the development of low-cost minimally-invasive tests that will be available to much wider patient populations.
This report gives a comprehensive and up-to-date analysis of new findings relating to the discovery and clinical evaluation of AD-related biomarkers with potential to allow early detection or progression of this disease, based on minimally-invasive or non-invasive methods. With a focus on controlled human studies of AD, these biomarker findings are 'functionally reviewed' alongside drugs and drug candidates in the development pipeline, and a market analysis of applicable (minimally-invasive) AD-related diagnostics tests, platforms and developments. This report also includes an analysis of related opportunities in AD research, drug discovery, clinical trials and clinical diagnostics.
Key Topics Covered:
Chapter 1. Background
Chapter 2. Blood Biomarkers
Chapter 3. Autoantibodies
Chapter 4. Urinary Biomarkers
Chapter 5. Salivary Biomarkers
Chapter 6. Other Biomarkers
Chapter 7. AD Drug Pipeline
Chapter 8. Diagnostics Companies of Minimally-Invasive AD Diagnostics
Chapter 9. An Integrated Analysis of AD Biomarkers
Chapter 10. Conclusions and Opportunities
For more information visit http://www.researchandmarkets.com/research/mh4stv/_earlystage
Media Contact: Laura Wood, +353-1-481-1716, [email protected]
Health care systems across the globe are under enormous strain, as facilities reach capacity and costs continue to rise. M2M and the Internet of Things have the potential to transform the industry through connected health solutions that can make care more efficient while reducing costs. In fact, Vodafone's annual M2M Barometer Report forecasts M2M applications rising to 57 percent in health care and life sciences by 2016. Lively is one of Vodafone's health care partners, whose solutions enable o...
Jun. 3, 2015 06:30 PM EDT Reads: 3,045
"People are a lot more knowledgeable about APIs now. There are two types of people who work with APIs - IT people who want to use APIs for something internal and the product managers who want to do something outside APIs for people to connect to them," explained Roberto Medrano, Executive Vice President at SOA Software, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Jun. 3, 2015 06:15 PM EDT Reads: 4,670
Jun. 3, 2015 06:00 PM EDT Reads: 712
Jun. 3, 2015 06:00 PM EDT Reads: 4,331
Jun. 3, 2015 06:00 PM EDT Reads: 678
Jun. 3, 2015 06:00 PM EDT Reads: 657
Jun. 3, 2015 05:15 PM EDT Reads: 4,268
Jun. 3, 2015 05:00 PM EDT Reads: 4,595
Jun. 3, 2015 05:00 PM EDT Reads: 429
Jun. 3, 2015 04:30 PM EDT Reads: 1,250
Jun. 3, 2015 04:19 PM EDT Reads: 426
Jun. 3, 2015 04:00 PM EDT Reads: 1,103
Jun. 3, 2015 04:00 PM EDT Reads: 2,232
Jun. 3, 2015 04:00 PM EDT Reads: 5,032
Jun. 3, 2015 04:00 PM EDT Reads: 1,161